Addex Therapeutics (ADXN) Reveals Promising Preclinical Results for Chronic Cough Treatment
The company announced promising preclinical findings regarding its GABAB positive allosteric modulator (ADX71441), which demonstrated significant antitussive effects in a model simulating chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Study Details and Findings
The study involved daily administration of the candidate to animals exposed to bleomycin, resulting in noteworthy reductions in cough frequency and improvements in lung pathology.
The recent findings from Addex Therapeutics are significant as they highlight the potential of the company's leading candidate to address chronic cough, a common symptom in patients with idiopathic pulmonary fibrosis. The study's results showed not only a reduction in cough frequency but also improvements in lung pathology, as evidenced by lower Ashcroft scores and a decrease in fibrotic lung tissue.
These findings could pave the way for further clinical trials and eventual commercialization of the drug, which would be a notable advancement in the treatment of a challenging condition.
About ADX71441 and Addex Therapeutics
ADX71441 is an orally active, blood-brain barrier penetrant positive allosteric modulator of GABAB receptor. ADX71441 potentiates the activity of endogenous GABA at GABAB receptor, with an EC50 of 96 nM. Additionally, ADX71441 functionally inhibits adenosine transporters and 5-HT2B receptor. ADX71441 produces anxiolytic-like, analgesic, muscle relaxant, hypothermic and overactive bladder inhibitory effects, reduces acute locomotor activity levels, decreases voluntary intake of alcohol and saccharin, attenuates stress-induced neuronal activation, and exhibits anti-hyperalgesic activity.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing allosteric modulators, a novel class of small-molecule drugs. With a market capitalization of approximately $8.29 million, the company operates primarily in Switzerland and Europe, concentrating on the discovery and development of pharmaceutical products aimed at improving human health.
